Vancomycin is a glycopeptide antibiotic commonly used in combination with other β‐lactam antibiotics, such as piperacillin–tazobactam (PTZ), as the initial empiric treatment for moderate–severe infections whenever coverage for both methicillin‐resistant Staphylococcus aureus and Pseudomonas aeruginosa is required.Vancomycin use has long been reported to be associated with nephrotoxicity. The development of acute kidney injury (AKI) in hospitalized patients can increase both morbidity and mortality. The published incidence of vancomycin‐induced AKI ranges from 5% to 43%, depending largely on the population studied, the presence or absence of confounding risk factors, and definitions of nephrotoxicity. In contrast, the reported incidence of AKI in patients receiving PTZ monotherapy is <1%.Several risk factors that increase the risk of vancomycin nephrotoxicity have been identified, including concomitant nephrotoxic agents, pre‐existing renal dysfunction, concomitant critical illness, increasing treatment duration, higher vancomycin serum trough concentration (>15 μg/mL), and total vancomycin dosage >4 g/day in adults.The exact mechanism of vancomycin nephrotoxicity is still uncertain. Vancomycin is primarily eliminated by glomerular filtration and some active tubular secretion. Postulated mechanisms include oxidative stress, complement‐mediated inflammation, and necrosis of the renal tubule with vancomycin accumulation. Published reports evaluating PTZ nephrotoxic potential are sparse. PTZ has been implicated in AKI through acute interstitial nephritis (AIN)
Pediatrics International – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera